• Je něco špatně v tomto záznamu ?

A Comprehensive Clinicopathologic and Molecular Reappraisal of GLI1 -altered Mesenchymal Tumors with Pooled Outcome Analysis Showing Poor Survival in GLI1 - amplified Versus GLI1- rearranged Tumors

C. Saoud, A. Agaimy, JK. Dermawan, JF. Chen, MK. Rosenblum, BC. Dickson, N. Dashti, M. Michal, K. Kosemehmetoglu, NU. Din, K. Albritton, NP. Agaram, CR. Antonescu

. 2024 ; 48 (10) : 1302-1317. [pub] 20240627

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, srovnávací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018797

GLI1 -altered mesenchymal tumor is a recently described distinct pathologic entity with an established risk of malignancy, being defined molecularly by either GLI1 gene fusions or amplifications. The clinicopathologic overlap of tumors driven by the 2 seemingly distinct mechanisms of GLI1 activation is still emerging. Herein, we report the largest series of molecularly confirmed GLI1 -altered mesenchymal neoplasms to date, including 23 GLI1- amplified and 15 GLI1 -rearranged new cases, and perform a comparative clinicopathologic, genomic, and survival investigation. GLI1- rearranged tumors occurred in younger patients (42 vs. 52 y) and were larger compared with GLI1 -amplified tumors (5.6 cm vs. 1.5 cm, respectively). Histologic features were overall similar between the 2 groups, showing a multinodular pattern and a nested architecture of epithelioid, and less commonly spindle cells, surrounded by a rich capillary network. A distinct whorling pattern was noted among 3 GLI1 -amplified tumors. Scattered pleomorphic giant cells were rarely seen in both groups. The immunoprofile showed consistent expression of CD56, with variable S100, CD10 and SMA expression. Genomically, both groups had overall low mutation burdens, with rare TP53 mutations seen only in GLI1- amplified tumors. GLI1 -amplified mesenchymal tumors exhibit mostly a single amplicon at the 12q13-15 locus, compared with dedifferentiated liposarcoma, which showed a 2-peak amplification centered around CDK4 (12q14.1) and MDM2 (12q15). GLI1 -amplified tumors had a significantly higher GLI1 mRNA expression compared with GLI1 -rearranged tumors. Survival pooled analysis of current and published cases (n=83) showed a worse overall survival in GLI1 -amplified patients, with 16% succumbing to disease compared with 1.7% in the GLI1- rearranged group. Despite comparable progression rates, GLI1 -amplified tumors had a shorter median progression-free survival compared with GLI1 -rearranged tumors (25 mo vs. 77 mo). Univariate analysis showed that traditional histologic predictors of malignancy (mitotic count ≥4/10 high-power fields, presence of necrosis, and tumor size ≥5 cm) are associated with worse prognosis among GLI1 -altered mesenchymal tumors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018797
003      
CZ-PrNML
005      
20241024111319.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/PAS.0000000000002272 $2 doi
035    __
$a (PubMed)38934567
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Saoud, Carla $u Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
245    12
$a A Comprehensive Clinicopathologic and Molecular Reappraisal of GLI1 -altered Mesenchymal Tumors with Pooled Outcome Analysis Showing Poor Survival in GLI1 - amplified Versus GLI1- rearranged Tumors / $c C. Saoud, A. Agaimy, JK. Dermawan, JF. Chen, MK. Rosenblum, BC. Dickson, N. Dashti, M. Michal, K. Kosemehmetoglu, NU. Din, K. Albritton, NP. Agaram, CR. Antonescu
520    9_
$a GLI1 -altered mesenchymal tumor is a recently described distinct pathologic entity with an established risk of malignancy, being defined molecularly by either GLI1 gene fusions or amplifications. The clinicopathologic overlap of tumors driven by the 2 seemingly distinct mechanisms of GLI1 activation is still emerging. Herein, we report the largest series of molecularly confirmed GLI1 -altered mesenchymal neoplasms to date, including 23 GLI1- amplified and 15 GLI1 -rearranged new cases, and perform a comparative clinicopathologic, genomic, and survival investigation. GLI1- rearranged tumors occurred in younger patients (42 vs. 52 y) and were larger compared with GLI1 -amplified tumors (5.6 cm vs. 1.5 cm, respectively). Histologic features were overall similar between the 2 groups, showing a multinodular pattern and a nested architecture of epithelioid, and less commonly spindle cells, surrounded by a rich capillary network. A distinct whorling pattern was noted among 3 GLI1 -amplified tumors. Scattered pleomorphic giant cells were rarely seen in both groups. The immunoprofile showed consistent expression of CD56, with variable S100, CD10 and SMA expression. Genomically, both groups had overall low mutation burdens, with rare TP53 mutations seen only in GLI1- amplified tumors. GLI1 -amplified mesenchymal tumors exhibit mostly a single amplicon at the 12q13-15 locus, compared with dedifferentiated liposarcoma, which showed a 2-peak amplification centered around CDK4 (12q14.1) and MDM2 (12q15). GLI1 -amplified tumors had a significantly higher GLI1 mRNA expression compared with GLI1 -rearranged tumors. Survival pooled analysis of current and published cases (n=83) showed a worse overall survival in GLI1 -amplified patients, with 16% succumbing to disease compared with 1.7% in the GLI1- rearranged group. Despite comparable progression rates, GLI1 -amplified tumors had a shorter median progression-free survival compared with GLI1 -rearranged tumors (25 mo vs. 77 mo). Univariate analysis showed that traditional histologic predictors of malignancy (mitotic count ≥4/10 high-power fields, presence of necrosis, and tumor size ≥5 cm) are associated with worse prognosis among GLI1 -altered mesenchymal tumors.
650    _2
$a lidé $7 D006801
650    12
$a protein Gli1 $x genetika $7 D000071676
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dospělí $7 D000328
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a genová přestavba $7 D015321
650    _2
$a senioři $7 D000368
650    12
$a nádorové biomarkery $x genetika $7 D014408
650    12
$a amplifikace genu $7 D005784
650    _2
$a mladý dospělý $7 D055815
650    _2
$a nádory měkkých tkání $x genetika $x patologie $x mortalita $7 D012983
650    _2
$a mladiství $7 D000293
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a časové faktory $7 D013997
650    _2
$a fenotyp $7 D010641
650    _2
$a senioři nad 80 let $7 D000369
655    _2
$a časopisecké články $7 D016428
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Agaimy, Abbas $u Institute of Pathology, Erlangen University Hospital, Comprehensive Cancer Center, European Metropolitan Area Erlangen-Nuremberg, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany
700    1_
$a Dermawan, Josephine K $u Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH
700    1_
$a Chen, Jie-Fu $u Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
700    1_
$a Rosenblum, Marc K $u Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
700    1_
$a Dickson, Brendan C $u Department of Laboratory Medicine and Pathology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
700    1_
$a Dashti, Nooshin $u Department of Pathology and Laboratory Medicine, Geisel School of Medicine at Dartmouth, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
700    1_
$a Michal, Michael $u Department of Pathology, Charles University, Faculty of Medicine in Plzeň, Czech Republic; Bioptical Laboratory, Ltd, Plzeň, Czech Republic $u Bioptical Laboratory, Ltd, Plzeň, Czech Republic
700    1_
$a Kosemehmetoglu, Kemal $u Department of Pathology, Hacettepe University, Ankara, Turkey
700    1_
$a Din, Nasir Ud $u Department of Pathology and Laboratory Medicine, Aga Khan University Hospital, Karachi, Pakistan
700    1_
$a Albritton, Karen $u Adolescent and Young Adult Oncology, Cook Children's Medical Center, Fort Worth, TX
700    1_
$a Agaram, Narasimhan P $u Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
700    1_
$a Antonescu, Cristina R $u Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
773    0_
$w MED00000304 $t The American journal of surgical pathology $x 1532-0979 $g Roč. 48, č. 10 (2024), s. 1302-1317
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38934567 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111313 $b ABA008
999    __
$a ok $b bmc $g 2201575 $s 1230770
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 48 $c 10 $d 1302-1317 $e 20240627 $i 1532-0979 $m The American journal of surgical pathology $n Am J Surg Pathol $x MED00000304
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace